30 closest matches · ranked by relevance
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Leukemia
Primary: Complete Response Rate — 89 percentage of patients
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. — 91.6; 90.7 Percentage of…
Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia, BCR-ABL1-Like · Central Nervous System Leukemia
Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…
Leukemia
Primary: Continuous Complete Remission at 1 Year — 21 participants
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Leukemia
Primary: Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy — 91 percentage of analyzable subjects
Lymphoblastic Leukemia, Acute, Childhood · Lymphoblastic Lymphoma · Peripheral T-cell Lymphoma
Primary: Number of Patients That Experienced DLT During Cycle 1 of Therapy — 3; 3; 5; 3 Participants
Acute Lymphoblastic Leukemia · Acute Undifferentiated Leukemia · Childhood T Acute Lymphoblastic Leukemia
Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Leukemia
Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Leukemia
Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05
T-cell Acute Lymphoblastic Leukemia · T-cell Lymphoblastic Lymphoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 2; 2; 3 Participants
Leukemia
Primary: Event-free Survival — 64.9; 70 percentage of participants
Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Event-free Survival Rate (EFS) — 21.3 Months
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Primary: Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy — 79.8; 83.2; 66.7 Percent probability
B Precursor Type Acute Leukemia
Primary: Fat Mass — 5.1; 10.7 percent change in fat mass
Acute Lymphoblastic Leukemia
Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Acute Lymphoblastic Leukemia · Adult B Lymphoblastic Lymphoma · Ann Arbor Stage I B Lymphoblastic Lymphoma
Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability
Leukemia
Primary: Complete Remission — 52 percentage of participants